24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Medical Disorders
Resources
Basic InformationLookupsLatest News
Two Lives Saved in Rare 'Paired' Liver DonationYour Life Span May Be Foretold in Your Heart BeatsHealth Tip: Stopping NosebleedsKids Can Get UTIs, TooIs a New Remedy for Body Odor on the Horizon?Why More Patients Are Surviving an AneurysmCommon Diabetes Drug May Also Shield Kidneys, HeartIsraeli Team Announces First 3D-Printed Heart Using Human Cells'Added Sugars' Label on Foods Could Save Many LivesCPAP Brings Longer Life for Obese People With Sleep Apnea: StudyYoung Athletes Need to Be Sidelined After Bout of MonoPre-Cut Melons at Kroger, Walmart, Other Stores May Carry SalmonellaCDC Says Ground Beef Is Source of E. coli Outbreak, Cases Rise to 109AHA News: Is Yoga Heart-Healthy? It's No Stretch to See Benefits, Science SuggestsFDA Orders Label Warning on Alcohol Use With 'Female Viagra'Could Treating Gut Bacteria Help Ease Autism Symptoms?Hospital Privacy Curtains Could Be Breeding Ground for GermsItchy Skin Common Alongside Kidney DiseaseMany Misdiagnosed With MSVehicle Exhaust Drives Millions of New Asthma Cases AnnuallyNFL Retirees Help Scientists Develop Early Test for Brain Condition CTEMigraine Pain Linked to Raised Suicide RiskMore Time Spent in Sports, Faster Healing From ConcussionHealth Tip: Thermometer OptionsStill No Source as E. Coli Outbreak Grows to 96 Cases Across 5 States: CDCClimate Change Could Worsen Sneezin' SeasonEvenity Approved for Osteoporotic WomenNYC Declares Public Health Emergency Over Brooklyn Measles OutbreakInsurers' Denials of Opioid Coverage Spurs CDC to Clarify GuidelinesImmune-Targeted Treatment Might Help Prevent Peanut Allergy CrisesCluster of Dangerous Antibiotic-Resistant E. Coli Infection Spotted in NYCHealth Tip: Managing Chronic MigrainesFor One Man, Too Much Vitamin D Was DisastrousCDC Investigates Mystery E. Coli Outbreak Affecting 5 StatesBlacks Live Longer, Not Necessarily Better, With ALSIs It Heartburn or Something Else?Lungs, Hearts Infected With Hepatitis C Still OK for TransplantUnhealthy Diets May Be World's Biggest KillerSevere 'Mono' Infection May Raise Risk for Chronic Fatigue SyndromeUnder-the-Tongue Allergy Pills Replacing Shots for ManyFish Slime Could Hold Key to Beating 'Superbug' InfectionsPet Hedgehogs Still Spreading Salmonella, CDC WarnsCimzia Approved for Inflammatory ArthritisSpring Is the Sneezing SeasonU.S. Flu Season Ebbing, but Cases Still Widespread: CDCLab-Grown Blood Vessels Could Be Big Medical AdvanceClimate Change Will Aid Spread of Disease-Bearing MosquitoesSurgeons Perform First HIV-Positive Kidney Transplant From Living DonorAncestry Matters When Seeking Matched Bone Marrow DonorsBad Info May Be Scaring Patients Away From Heart-Healthy Statins
Questions and AnswersLinks
Related Topics

Diabetes

Cablivi Approved for Rare Clotting Disorder

HealthDay News
by -- Scott Roberts
Updated: Feb 6th 2019

WEDNESDAY, Feb. 6, 2019 (HealthDay News) -- Cablivi (caplacizumab-yhdp) injection has been approved by the U.S. Food and Drug Administration to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and deadly disorder that causes blood clotting.

"Patients with aTTP endure hours of treatment with daily plasma exchange, which requires being attached to a machine that takes blood out of the body and mixes it with donated plasma and then returns it to the body. Even after days or weeks of this treatment, as well as taking drugs that suppress the immune system, many patients will have a recurrence of aTTP," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence.

People with aTTP develop blood clots in the small blood vessels throughout the body. The clots can cut off oxygen and blood supply to the major organs and cause strokes and heart attacks, the agency said Wednesday in a news release. Patients with cancer, HIV, pregnancy, lupus or infections are at greater risk of developing the disorder.

Cablivi was evaluated in clinical studies involving 145 people. Those treated with Cablivi had fewer instances of aTTP-related death, the FDA said.

Common side effects include headache and bleeding of the nose or gums.

Cablivi's prescribing information includes a warning about the risk of severe bleeding. Health care providers should monitor closely people who also take blood-thinning medications, the FDA said.

The drug is produced by Ablynx, based in Belgium.